{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:51:36Z","timestamp":1769082696106,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s11060-021-03720-y","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T09:03:42Z","timestamp":1614848622000},"page":"523-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fluid attenuation in non\u2010contrast\u2010enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma"],"prefix":"10.1007","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-4362","authenticated-orcid":false,"given":"Sohil H.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem P.","family":"Batchala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J. Eluvathingal","family":"Muttikkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio S.","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Patrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo E.","family":"Fadul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Beatriz","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"3720_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803\u2013820","journal-title":"Acta Neuropathol"},{"key":"3720_CR2","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807\u20131812","journal-title":"Science"},{"key":"3720_CR3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765\u2013773","journal-title":"N Engl J Med"},{"key":"3720_CR4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa1402121","volume":"372","author":"DJ Brat","year":"2015","unstructured":"Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481\u20132498","journal-title":"N Engl J Med"},{"key":"3720_CR5","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","volume":"372","author":"JE Eckel-Passow","year":"2015","unstructured":"Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p\/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499\u20132508","journal-title":"N Engl J Med"},{"key":"3720_CR6","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM et al (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550\u2013563","journal-title":"Cell"},{"key":"3720_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1148\/radiol.2017151930","volume":"284","author":"M Smits","year":"2017","unstructured":"Smits M, van den Bent MJ (2017) Imaging correlates of adult glioma genotypes. Radiology 284:316\u2013331","journal-title":"Radiology"},{"key":"3720_CR8","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s00330-018-5608-7","volume":"29","author":"CH Suh","year":"2019","unstructured":"Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ (2019) Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis. Eur Radiol 29:745\u2013758","journal-title":"Eur Radiol"},{"key":"3720_CR9","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1158\/1078-0432.CCR-13-0017","volume":"19","author":"C Hartmann","year":"2013","unstructured":"Hartmann C, Hentschel B, Simon M et al (2013) Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 19:5146\u20135157","journal-title":"Clin Cancer Res"},{"key":"3720_CR10","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00401-013-1163-0","volume":"126","author":"N Nonoguchi","year":"2013","unstructured":"Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126:931\u2013937","journal-title":"Acta Neuropathol"},{"key":"3720_CR11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","volume":"19","author":"H Ohgaki","year":"2013","unstructured":"Ohgaki H, Kleihues P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764\u2013772","journal-title":"Clin Cancer Res"},{"key":"3720_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/neuonc\/not159","volume":"16","author":"J Beiko","year":"2014","unstructured":"Beiko J, Suki D, Hess KR et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81\u201391","journal-title":"Neuro Oncol"},{"key":"3720_CR13","doi-asserted-by":"crossref","first-page":"6078","DOI":"10.1158\/1078-0432.CCR-17-0560","volume":"23","author":"SH Patel","year":"2017","unstructured":"Patel SH, Poisson LM, Brat DJ et al (2017) T2-FLAIR mismatch, an imaging biomarker for IDH and 1p\/19q status in lower-grade gliomas: a TCGA\/TCIA project. Clin Cancer Res 23:6078\u20136085","journal-title":"Clin Cancer Res"},{"key":"3720_CR14","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1093\/neuonc\/noy048","volume":"20","author":"MPG Broen","year":"2018","unstructured":"Broen MPG, Smits M, Wijnenga MMJ et al (2018) The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p\/19q-intact lower grade glioma: a validation study. Neuro Oncol 20:1393\u20131399","journal-title":"Neuro Oncol"},{"key":"3720_CR15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3174\/ajnr.A5572","volume":"39","author":"A Lasocki","year":"2018","unstructured":"Lasocki A, Gaillard F, Gorelik A, Gonzales M (2018) MRI features can predict 1p\/19q status in intracranial gliomas. AJNR Am J Neuroradiol 39:687\u2013692","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR16","first-page":"426","volume":"40","author":"PP Batchala","year":"2019","unstructured":"Batchala PP, Muttikkal TJE, Donahue JH et al (2019) Neuroimaging-based classification algorithm for predicting 1p\/19q-codeletion status in IDH-mutant lower grade gliomas. AJNR Am J Neuroradiol 40:426\u2013432","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12885-020-06951-w","volume":"20","author":"A Corell","year":"2020","unstructured":"Corell A, Ferreyra Vega S, Hoefling N et al (2020) The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. BMC Cancer 20:450","journal-title":"BMC Cancer"},{"key":"3720_CR18","first-page":"vdaa004","volume":"2","author":"M Foltyn","year":"2020","unstructured":"Foltyn M, Nieto Taborda KN, Neuberger U et al (2020) T2\/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p\/19q non-codeleted gliomas: validity and pathophysiology. Neurooncol Adv. 2:vdaa004","journal-title":"Neurooncol Adv."},{"key":"3720_CR19","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/neuonc\/noaa041","volume":"22","author":"R Jain","year":"2020","unstructured":"Jain R, Johnson DR, Patel SH et al (2020) \u201cReal world\u201d use of a highly reliable imaging sign: \u201cT2-FLAIR mismatch\u201d for identification of IDH mutant astrocytomas. Neuro Oncol 22:936\u2013943","journal-title":"Neuro Oncol"},{"key":"3720_CR20","doi-asserted-by":"publisher","DOI":"10.2463\/mrms.bc.2019-0196","author":"M Kinoshita","year":"2020","unstructured":"Kinoshita M, Uchikoshi M, Sakai M, Kanemura Y, Kishima H, Nakanishi K (2020) T2-FLAIR mismatch sign is caused by long T1 and T2 of IDH-mutant, 1p19q non-codeleted astrocytoma. Magn Reson Med Sci. https:\/\/doi.org\/10.2463\/mrms.bc.2019-0196","journal-title":"Magn Reson Med Sci"},{"key":"3720_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1148\/radiol.2019191140","volume":"294","author":"SH Patel","year":"2020","unstructured":"Patel SH, Batchala PP, Mrachek EKS et al (2020) MRI and CT identify isocitrate dehydrogenase (IDH)-mutant lower-grade gliomas misclassified to 1p\/19q codeletion status with fluorescence in situ hybridization. Radiology 294:160\u2013167","journal-title":"Radiology"},{"key":"3720_CR22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11060-020-03611-8","volume":"149","author":"E Aliotta","year":"2020","unstructured":"Aliotta E, Dutta SW, Feng X et al (2020) Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign. J Neuro-oncol. 149:325\u2013335","journal-title":"J Neuro-oncol."},{"key":"3720_CR23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3174\/ajnr.A6025","volume":"40","author":"A Lasocki","year":"2019","unstructured":"Lasocki A, Gaillard F (2019) Non-contrast-enhancing tumor: a new frontier in glioblastoma research. AJNR Am J Neuroradiol 40:758\u2013765","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3174\/ajnr.A2950","volume":"33","author":"JA Carrillo","year":"2012","unstructured":"Carrillo JA, Lai A, Nghiemphu PL et al (2012) Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma. AJNR Am J Neuroradiol 33:1349\u20131355","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR25","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1200\/JCO.2010.33.8715","volume":"29","author":"A Lai","year":"2011","unstructured":"Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482\u20134490","journal-title":"J Clin Oncol"},{"key":"3720_CR26","doi-asserted-by":"crossref","first-page":"153303381987716","DOI":"10.1177\/1533033819877167","volume":"18","author":"H Ding","year":"2019","unstructured":"Ding H, Huang Y, Li Z et al (2019) Prediction of IDH status through MRI features and enlightened reflection on the delineation of target volume in low-grade gliomas. Technol Cancer Res Treat 18:1533033819877167","journal-title":"Technol Cancer Res Treat"},{"key":"3720_CR27","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3892\/ol.2014.2013","volume":"7","author":"S Qi","year":"2014","unstructured":"Qi S, Yu L, Li H et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7:1895\u20131902","journal-title":"Oncol Lett"},{"key":"3720_CR28","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/j.wneu.2018.10.075","volume":"122","author":"Y Ahmadipour","year":"2019","unstructured":"Ahmadipour Y, Jabbarli R, Gembruch O et al (2019) Impact of multifocality and molecular markers on survival of glioblastoma. World Neurosurg 122:e461\u2013e466","journal-title":"World Neurosurg"},{"key":"3720_CR29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jocn.2017.01.007","volume":"39","author":"A Lasocki","year":"2017","unstructured":"Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S (2017) Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 39:170\u2013175","journal-title":"J Clin Neurosci"},{"key":"3720_CR30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nov239","volume":"18","author":"K Wang","year":"2016","unstructured":"Wang K, Wang Y, Fan X et al (2016) Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients. Neuro Oncol 18:589\u2013597","journal-title":"Neuro Oncol"},{"key":"3720_CR31","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1177\/0284185119842288","volume":"60","author":"Z Xing","year":"2019","unstructured":"Xing Z, Zhang H, She D et al (2019) IDH genotypes differentiation in glioblastomas using DWI and DSC-PWI in the enhancing and peri-enhancing region. Acta Radiol 60:1663\u20131672","journal-title":"Acta Radiol"},{"key":"3720_CR32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3174\/ajnr.A4491","volume":"37","author":"K Yamashita","year":"2016","unstructured":"Yamashita K, Hiwatashi A, Togao O et al (2016) MR imaging-based analysis of glioblastoma multiforme: estimation of IDH1 mutation status. AJNR Am J Neuroradiol 37:58\u201365","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1750-3639.2009.00352.x","volume":"20","author":"D Capper","year":"2010","unstructured":"Capper D, Weissert S, Balss J et al (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245\u2013254","journal-title":"Brain Pathol"},{"key":"3720_CR34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","volume":"118","author":"D Capper","year":"2009","unstructured":"Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599\u2013601","journal-title":"Acta Neuropathol"},{"key":"3720_CR35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00401-010-0647-4","volume":"119","author":"J Felsberg","year":"2010","unstructured":"Felsberg J, Wolter M, Seul H et al (2010) Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501\u2013507","journal-title":"Acta Neuropathol"},{"key":"3720_CR36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5858\/2010-0649-RAIR.1","volume":"135","author":"MN Nikiforova","year":"2011","unstructured":"Nikiforova MN, Hamilton RL (2011) Molecular diagnostic of gliomas. Arch Pathol Lab Med 135:558\u2013568","journal-title":"Arch Pathol Lab Med"},{"key":"3720_CR37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1227\/NEU.0000000000000200","volume":"74","author":"JM Sarmiento","year":"2014","unstructured":"Sarmiento JM, Nuno M, Ortega A et al (2014) Cystic glioblastoma: an evaluation of IDH1 status and prognosis. Neurosurgery 74:71\u201375","journal-title":"Neurosurgery"},{"key":"3720_CR38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3171\/jns.2004.100.1.0061","volume":"100","author":"MV Maldaun","year":"2004","unstructured":"Maldaun MV, Suki D, Lang FF et al (2004) Cystic glioblastoma multiforme: survival outcomes in 22 cases. J Neurosurg 100:61\u201367","journal-title":"J Neurosurg"},{"key":"3720_CR39","doi-asserted-by":"crossref","first-page":"e7154","DOI":"10.7717\/peerj.7154","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang J, Li F, Xu X, Xu B (2019) Diagnostic performance of clinical properties and conventional magnetic resonance imaging for determining the IDH1 mutation status in glioblastoma: a retrospective study. PeerJ 7:e7154","journal-title":"PeerJ"},{"key":"3720_CR40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11060-014-1614-z","volume":"121","author":"S Lee","year":"2015","unstructured":"Lee S, Choi SH, Ryoo I et al (2015) Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1\/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging. J Neurooncol 121:141\u2013150","journal-title":"J Neurooncol"},{"key":"3720_CR41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/jmri.25358","volume":"45","author":"W Tan","year":"2017","unstructured":"Tan W, Xiong J, Huang W, Wu J, Zhan S, Geng D (2017) Noninvasively detecting Isocitrate dehydrogenase 1 gene status in astrocytoma by dynamic susceptibility contrast MRI. J Magn Reson Imaging 45:492\u2013499","journal-title":"J Magn Reson Imaging"},{"key":"3720_CR42","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00330-019-06379-2","volume":"30","author":"RE Yoo","year":"2020","unstructured":"Yoo RE, Yun TJ, Hwang I et al (2020) Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas. Eur Radiol 30:1202\u20131211","journal-title":"Eur Radiol"},{"key":"3720_CR43","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10143-017-0908-y","volume":"41","author":"M Natsumeda","year":"2018","unstructured":"Natsumeda M, Motohashi K, Igarashi H et al (2018) Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. Neurosurg Rev 41:641\u2013647","journal-title":"Neurosurg Rev"},{"key":"3720_CR44","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1002\/cam4.1863","volume":"7","author":"ZC Li","year":"2018","unstructured":"Li ZC, Bai H, Sun Q et al (2018) Multiregional radiomics profiling from multiparametric MRI: identifying an imaging predictor of IDH1 mutation status in glioblastoma. Cancer Med 7:5999\u20136009","journal-title":"Cancer Med"},{"key":"3720_CR45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/now121","volume":"19","author":"B Zhang","year":"2017","unstructured":"Zhang B, Chang K, Ramkissoon S et al (2017) Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 19:109\u2013117","journal-title":"Neuro Oncol"},{"key":"3720_CR46","doi-asserted-by":"crossref","first-page":"e19123","DOI":"10.1097\/MD.0000000000019123","volume":"99","author":"CM Lo","year":"2020","unstructured":"Lo CM, Weng RC, Cheng SJ, Wang HJ, Hsieh KL (2020) Computer-aided diagnosis of isocitrate dehydrogenase genotypes in glioblastomas from radiomic patterns. Medicine (Baltimore) 99:e19123","journal-title":"Medicine (Baltimore)"},{"key":"3720_CR47","doi-asserted-by":"crossref","first-page":"45888","DOI":"10.18632\/oncotarget.17585","volume":"8","author":"KL Hsieh","year":"2017","unstructured":"Hsieh KL, Chen CY, Lo CM (2017) Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas. Oncotarget 8:45888\u201345897","journal-title":"Oncotarget"},{"key":"3720_CR48","first-page":"1439","volume":"39","author":"CH Suh","year":"2018","unstructured":"Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ (2018) Clinically relevant imaging features for MGMT promoter methylation in multiple glioblastoma studies: a systematic review and meta-analysis. AJNR Am J Neuroradiol 39:1439\u20131445","journal-title":"AJNR Am J Neuroradiol"},{"key":"3720_CR49","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","volume":"30","author":"DN Louis","year":"2020","unstructured":"Louis DN, Wesseling P, Aldape K et al (2020) cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 30:844\u2013856","journal-title":"Brain Pathol"},{"key":"3720_CR50","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/nox078","volume":"19","author":"A Aibaidula","year":"2017","unstructured":"Aibaidula A, Chan AK, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncol 19:1327\u20131337","journal-title":"Neuro Oncol"},{"key":"3720_CR51","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","volume":"139","author":"DJ Brat","year":"2020","unstructured":"Brat DJ, Aldape K, Colman H et al (2020) cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 139:603\u2013608","journal-title":"Acta Neuropathol"},{"key":"3720_CR52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","volume":"136","author":"DJ Brat","year":"2018","unstructured":"Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.\u201d Acta Neuropathol 136:805\u2013810","journal-title":"Acta Neuropathol"},{"key":"3720_CR53","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10143-018-0996-3","volume":"43","author":"DT Di Carlo","year":"2018","unstructured":"Di Carlo DT, Duffau H, Cagnazzo F, Benedetto N, Morganti R, Perrini P (2018) IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis. Neurosurg Rev. 43:383","journal-title":"Neurosurg Rev."},{"key":"3720_CR54","first-page":"1","volume":"20","author":"G Poulen","year":"2018","unstructured":"Poulen G, Goze C, Rigau V, Duffau H (2018) Huge heterogeneity in survival in a subset of adult patients with resected, wild-type isocitrate dehydrogenase status, WHO grade II astrocytomas. J Neurosurg. 20:1\u201310","journal-title":"J Neurosurg."},{"key":"3720_CR55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-018-1849-4","volume":"136","author":"M Shirahata","year":"2018","unstructured":"Shirahata M, Ono T, Stichel D et al (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol 136:153\u2013166","journal-title":"Acta Neuropathol"},{"key":"3720_CR56","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/neuonc\/noz126.000","volume":"21","author":"R Appay","year":"2019","unstructured":"Appay R, Dehais C, Maurage CA et al (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519\u20131528","journal-title":"Neuro Oncol"},{"key":"3720_CR57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/nan.12523","volume":"45","author":"A Korshunov","year":"2019","unstructured":"Korshunov A, Casalini B, Chavez L et al (2019) Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathol Appl Neurobiol 45:108\u2013118","journal-title":"Neuropathol Appl Neurobiol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-021-03720-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03720-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T17:18:15Z","timestamp":1619716695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-021-03720-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03720-y","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"29 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sohil H. Patel, Prem P. Batchala, Thomas J. Eluvathingal Muttikkal, Sergio S. Ferrante, James T. Patrie, Camilo E. Fadul, David Schiff, M. Beatriz Lopes, Rajan Jain declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional Review Board approval was obtained for this retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}